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Introduction 
Propofol  (2,  6-diisopropylphenol)  is  a  rapid  acting 
anesthetic  drug  which  is  commonly  used  for  induction 
and  maintenance  of  anesthesia  and  for  sedation  in 
intensive care unit patients.
1,2 High clearance and large 
apparent volume of distribution of this drug make it a 
good controllable intravenous anesthetic agent.
3  
Pharmacokinetics  of  propofol  has  been  the  subject  of 
several studies. It shows a high degree of inter-individual 
variability  and  could  be  affected  by  factors  such  as 
patient age, sex and genetic polymorphism.
4-11 
A  fully  validated,  accurate  and  precise  method  for 
measurement of propofol in biological fluid is necessary 
for pharmacokinetic investigations on this drug. Various 
high-performance  liquid  chromatography  methods  with 
ultraviolet,
12-14  fluorescence,
14-18  mass 
spectrometry
12,14,19,20  and  electrochemical
12  detection 
have  been  reported  for  determination  of  propofol 
concentration in biological fluids.  
Since the quality of the bio analytical data is completely 
under  the  influence  of  the  calibration  model,  a  well-
designed and interpreted calibration curve in required for 
any analytical methodology.
21,22 Although the unknown 
concentrations of the analytes in biological samples are 
usually determined using linear calibration equations, in 
some  cases  the  use  of  nonlinear  models  should  be 
considered  especially  when  the  concentration  range  in 
the test samples is broad.
23,24 
Homoscedasticity or the equality of response uncertainty 
(or variances) over the entire concentration range is one 
of  the  basic  assumptions  of  ordinary  least  squares 
regression  method  that  is  usually  used  to  derive  the 
calibration  equations.  However,  this  condition  is  not 
usually  fulfilled  and  weighted  regression  is  used  to 
account  for  the  heteroscedasticity  of  the  measured 
response. It is clear that when the concentration range is 
broad, the variances of response values at different levels 
of concentration might be quite different.
22,25  
Very wide ranges of concentrations have been observed 
during  pharmacokinetic  studies  of  propofol.
5,7,9,26  In 
some studies, two calibration curves were constructed for 
lower  and  higher  ranges  of  propofol  concentration.
16 
Although  this  approach  is  common,
27-29  using  a  single 
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Abstract 
Purpose: The aim of this study was to select the best calibration model for determination of 
propofol plasma concentration by high-performance liquid chromatography method.  
Methods:  Determination  of  propofol  in  plasma  after  deproteinization  with  acetonitrile 
containing thymol (as internal standard) was carried out on a C18 column with a mixture of 
acetonitrile and trifluoroacetic acid 0.1% (60:40) as mobile phase which delivered at the 
flow rate of 1.2 mL/minute . Fluorescence detection was done at the excitation and emission 
wavelengths  of  276  and  310  nm,  respectively.  After  fitting  different  equations  to  the 
calibration data using weighted regression, the adequacy of models were assessed by lack-
of-fit  test,  significance  of  all  model  parameters,  adjusted  coefficient  of  determination 
(R
2
adjusted) and by measuring the predictive performance with median relative prediction 
error and median absolute relative prediction error of the validation data set.  
Results:  The  best  model  was  a  linear  equation  without  intercept  with  median  relative 
prediction error and median absolute relative prediction error of 4.0 and 9.4%, respectively 
in the range of 10-5000 ng/mL. The method showed good accuracy and precision.  
Conclusion: The presented statistical framework could be used to choose the best model for 
heteroscedastic  calibration  data  for  analytes  like  propofol  with  wide  range  of  expected 
concentration.  
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standard curve that encompasses the entire concentration 
range is preferred.  
This  study  was  designed  and  conducted  to  set  a  high-
performance  liquid  chromatography  method  for 
determination  of  propofol  in  human  plasma  with  the 
focus on selecting the best calibration equation. To do 
this, we assessed different linear and nonlinear models 
using  several  usual  weighting  schemes.  Standard 
statistical  approaches  for  checking  the  validity  and 
models  goodness  of  fit  were  used  to  choose  the  best 
calibration model as described in experimental section. 
 
Materials and Methods 
Chemicals 
Propofol  (≥97%)  was  obtained  from  Sigma-Aldrich, 
USA.  Thymol,  trifluoroacetic  acid  and  acetonitrile 
(HPLC-grade) were purchased from Merck, Germany.  
 
Preparation of standard solutions and plasma standards 
Stock  standard  solutions  of  1mg/mL  propofol  and  0.1 
mg/mL  thymol  (as  internal  standard)  were  prepared  in 
methanol  and  acetonitrile,  respectively  and  kept 
refrigerated. Then, a solution of 150 ng/mL thymol were 
made  by  further  dilution  of  its  stock  solution  with 
acetonitrile  and  used  as  the  working  internal  standard 
and precipitating agent. Standard solutions of propofol at 
the concentrations of 100, 200 ,500 ,1000 ,2500 ,5000 
,10000 ,25000 and 50000 ng/ml were made by dilution 
of  proper  volumes  of  stock  standard  with  methanol. 
Plasma standards of propofol were then prepared freshly 
by  spiking  900  µL  of  human  blank  plasma  with  the 
above standards to give the concentration range of 10 to 
5000 ng/mL. Plasma standards were stored at 4 °C until 
the time of analysis.  
 
Chromatography conditions 
Chromatography condition was similar to those reported 
by  Knibbe  et  al  with  some  modifications.
16  The  high-
performance  liquid  chromatography  system  consisted  of 
an  Agilent  1260  Infinity  quaternary  pump  and  Agilent 
1260  Infinity  fluorescence  detector  (Agilent,  USA).  A 
Capital ODS-H-Optimal 
® column (150 mm × 4.6 mm, 5 
μm particle size) (Capital HPLC Limited, UK) was used 
as  stationary  phase.  The  mobile  phase,  a  mixture  of 
acetonitrile and trifluoroacetic acid 0.1% (60:40, v/v), was 
degassed by ultra-sonication for 15 minutes before using 
and  delivered  at  the  flow  rate  of  1.2  mL/minute.  The 
excitation and emission wavelengths were set at 276 and 
310 nm, respectively. Chromatography was carried out at 
ambient temperature. 
 
Sample pretreatment 
Four hundred microliter of the working internal standard 
solution was added to 200 µL of plasma standard or real 
sample and vortex-mixed for  2 minutes. Samples  were 
then  centrifuged  at  10000  g  for  5  minutes.  The 
supernatant was separated and centrifuged for another 5 
minutes  .Fifty  microliter  of  the  clear  supernatant  was 
injected onto the chromatography column.  
Modeling the calibration curve and statistical analysis  
Calibration curves were constructed using the peak area 
ratios  of  propofol  to  internal  standard  (PAR)  as  the 
response  variable.  Five  replicates  of  independently 
spiked  propofol  plasma  standards  in  the  concentration 
range of 10 to 5000 ng/mL were analyzed and the results 
were  pooled  together  for  regression  analysis. 
Homoscedasticity  of  PAR  values  were  assessed  using 
Levene’s  test.
30  The  following  linear  and  nonlinear 
models
31 were fitted to the PAR–propofol concentration 
(C) data: 
2
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Five  different  weighting  schemes  including  1  (no 
weight),  1/C,  1/C
2,  1/PAR  and  1/PAR
2 were  used  for 
weighed regression analysis and denoted by subscripts 1-
5, respectively.
22,32 After fitting the candidate models to 
the calibration data, method proposed by Tse et al with 
some modifications were employed for selection of the 
best  model.
31  The  adequacy  of  the  models  were  first 
assessed  by  the  lack-of-fit  test  and  significance  of  all 
model parameters. Normality of the residuals were also 
checked by D'Agostino-Pearson normality test.
33 Models 
that  showed  significant  lack-of  –fit  test,  substantial 
deviation of residuals from normal distribution, had non-
significant  parameters
31  or  with  high  parameters 
dependency  (greater  than  0.99) 
34  were  excluded  from 
further  analysis.  Among  the  remaining  models,  those 
with  the  ratio  of  adjusted  R-squared  (R
2
adjusted) to  the 
maximum  observed  R
2
adjusted  greater  than  a  predefined 
value (0.8) were chosen.
31 
Another five replicates of propofol plasma standards at 
the  concentrations  of  10,  1000  and  5000  ng/mL  were 
prepared  and  analyzed.  The  calculated  concentrations 
with each of the selected models were compared with the 
nominal concentrations and the relative prediction error 
(PE%) was determined as follows: 
predicted nominal
nominal
% 100
CC
PE
C

  
In  which  Cpredicted and  Cnominal are  the  calibration  model 
predicted  and  nominal  concentrations  of  propofol, 
respectively.  Median  of  relative  prediction  errors  and 
median absolute relative prediction errors were used as 
measures  of  bias  and  precision.  These  metrics  of 
predictive performance  were  compared  by  constructing 
95% confidence interval around them.
35  
  
Results and Discussion 
Chromatograms  of  human  blank  plasma,  propofol 
plasma  standard  at  the  concentration  of  500  ng/mL  as 
well as a real sample obtained 3 minutes post termination  
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of a propofol infusion at the rate of 50 µg/minute (equal 
to  373  ng/mL)  are  shown  in  Figure  1  (A-C).  The 
retention  times  of  propofol  and  thymol  are  5.00±0.09 
(SD)  and  9.17±0.05  minutes,  respectively.  Analytical 
recovery  of  propofol  at  different  concentrations  was 
greater than 90%. 
 
 
Figure 1. Chromatograms of human blank plasma(A), propofol 
plasma  standard  at  the  concentration  of  500  ng/mL(B)  and  a 
sample  obtained  3  minutes  post  termination  of  a  propofol 
infusion at the rate of 50 µg/minute(equal to 373 ng/mL)(C) 
 
Homoscedasticity  of  PAR  values  at  different 
concentrations  of  propofol  was  rejected  (Levene 
statistic  =  28.7,  p-value<0.0001).  Plot  of  residuals 
against  propofol  concentration  (model  b1in  Figure  2) 
obtained  after  ordinary  regression  analysis  of  PAR-
concentration data further confirms the heterogeneity of 
response variance. Heteroscedastic nature of the PAR 
values at the different levels of propofol concentration 
make  the  use  of  weighted  least  squares  regression 
method to fit the calibration models inevitable. Fitting 
of  the  commonly  used  linear  model  (a1)  by  ordinary 
least  squares  regression  method  (with  no  weighting 
factor) led to calibration equation that predict propofol 
concentration  at  the  limit  of  the  quantitation  of  the 
method (10 ng/mL) with substantial relative prediction 
error (greater than 348%). Although this model ,like the 
majority of the models  in Table 1, has a rather good 
adjusted R-squared value and the ratio of its R
2
adjusted to 
the maximum observed R
2
adjusted is greater than 0.8, its 
predictive performance is not acceptable. As stated by 
other  investigators,  coefficient  of  determination  (R
2) 
might be quite misleading if it used as the only measure 
of  the  goodness  of  fit  and  quality  of  a  calibration 
equation without reference to factors such as pattern of 
calibration  data  points,  number  of  observations  , 
etc.
36,37  
Due to the wide range of propofol concentration that 
may  be  encountered  in  real  samples,  nonlinear 
calibration  equations  were  also  considered  in  the 
current  study.
24  Among  different  models  suggested 
elsewhere,
31  and  fitted  to  the  propofol  HPLC 
calibration data, the exponential models (f1-f5) showed 
significant lack-of-fit (p-value <0.0001) and low values 
of R
2
adjusted , therefore these models were left out. 
The intercepts of the linear equations (a1-a5) were not 
significantly  different  from  zero,  in  other  words  it 
seems  that  these  models  are  overparametrized  and 
simpler  models  should  be  taken  into  account. 
Overparametrization  of  the  calibration  model  lead  to 
instability  of  the  estimated  parameters  which  in  turn 
increase the variance of the calculated concentrations.
31 
As could be seen from Table 1, the same is true for the 
constants  of  the  quadratic  models  (c1-c5).  Also,  the 
quadratic  terms  of  these  equations  have  very  small 
values and in  case of models  c3 and c5  do not  differ 
significantly  from  zero.  Therefore,  the  quadratic 
calibration equations could not be used as predictor of 
propofol concentration in the unknown samples. 
Of the two power models (d and e) that were fitted to 
the data, models e1-e5 had a non-significant parameter 
()  and  could  be  simplified  to  models  d  (Table  1). 
Models d1-d5 all showed high R
2 but the parameters of 
d1  had  dependency  values  greater  than  0.99  that  is  a 
sign of model redundancy.
31 
It  is  now  generally  accepted  that  the  least  squares 
regression  of  heteroscedastic  data  needs  proper 
weighting factor to account for inequality of uncertainty 
in response variable that is very common in analytical 
methods  such  as  high-performance  liquid 
chromatography.  To  remove  the  heterogeneity  in 
response variability, different weight factors have been 
used.  If  enough  replicates  (a  minimum  of  ten)  of 
response variable are available at all levels of analyte 
concentrations, the common approach is to calculate the 
variance of the response and select the weight as the 
reciprocal  of  the  response  variance  at  each 
concentration. Due to the lack of such a large number 
of replicates, other empirical weights such as the ones 
used in the present study may be considered.
22,32,36 
A  good  weighting  factor  should  remove  the 
heterogeneity  of  the  response  variance  and  results  in 
models  with  acceptable  predictive  performance  as 
measured by median relative prediction error (bias) and 
median absolute relative prediction error (precision) of 
the estimated concentrations in the validation data set.
22  
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Statistically significant bias was not observed for any of 
the models as could be found from the 95 % confidence 
interval around the median relative prediction errors in 
Table  1.  Selection  of  the  best  weighting  factors  was 
carried  out  according  to  the  method  proposed  by 
Almeida et al with some modifications.
22 Assessment of 
the results of applying different weighting schemes on 
median  relative  prediction  error  of  propofol 
concentration (Table 2) reveals that for all models (a-e) 
the reciprocal of squared propofol concentration (1/C
2) 
or peak area ratio of the propofol to internal standard 
(1/PAR
2) led to the minimum bias and best precision of 
the  estimation.  It  has  been  reported  that  the  use  of 
relative  prediction  error  as  the  quality  coefficient  for 
choosing the best weight factor is predisposed to find 
proportional error in the data,
32 therefore in the current 
study,  in  addition  to  assessing  the  relative  prediction 
error of the concentration in the validation set, selection 
of the best weight factor was also based on statistical 
judgments such as the ability of the weighting scenario 
in  removing  the  heterogeneity  in  PAR  variance 
(stabilization of the response variance), having the least 
standard  error  of  the  estimate  (Sy.x)  and  passing  the 
normality test of the residuals (Table 1). As could be 
seen  from  Tables  1  and  2,  models  b3,  b5,  d3  and  d5 
which where fitted to the calibration data with weights 
equal to 1/C
2 or 1/PAR
2 have the least standard error of 
estimates among all models and their residuals do not 
significantly deviate from normal distribution. Plots of 
residuals against propofol  concentration are shown  in 
Figure 2 for the above mentioned models. Although all 
these fitted equations (b3, b5, d3 and d5) could stabilize 
the  variance  of  the  response  (PAR),  the  minimum 
residual  values  (Figure  2)  were  observed  for  models 
with  reciprocal  of  squared  concentration  as  the 
weighting factor. This fact could be also realized from 
Sy.x values (Table 1). 
 
 
Figure 2. Plots of mean residuals ± SD of models b1, b3, b5, d3 and d5 against propofol concentration 
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Table 1. Summary of the estimated parameters of models fitted to the propofol calibration data and the goodness of fit results (values in 
the parentheses are the 95% confidence intervals 
Model  Weight 
Model Parameters  Lack-of-fit 
§ Sy.x 
Normality of residuals 
(p-value) 
R
2
adjusted 
Parameter dependency 
      F  p-value       
a1  1  0.00227 
(0.00219,  0.00235) 
-0.0801 
(-0.2270, 0.0668) 
-  1.30  0.2669  0.4374  < 0.0001  0.9828  0.351  0.351  - 
a2  1/C 
0.00220 
(0.00213, 0.00226) 
-0.0051 
(-0.0216, 0.0115) 
-  1.91  0.0760  0.0078  < 0.0001  0.9878  0.055  0.055  - 
a3  1/C
2  0.00213 
(0.00206, 0.00220) 
-0.0011 
(-0.00327,0.00105) 
-  1.53  0.1666  0.0002  0.1461  0.9846  0.251  0.251  - 
a4  1/PAR 
0.00220 
(0.00213, 0.00226) 
-0.0046 
(-0.0199, 0.0107) 
-  1.91  0.0756  0.1669  < 0.0001  0.9878  0.050  0.050  - 
a5  1/PAR
2  0.00213 
(0.00205,  0.00220) 
-0.0011 
(-0.0031, 0.0010) 
-  1.51  0.1742  0.1101  0.1372  0.9844  0.260  0.260  - 
b1  1 
0.00224 
(0.00218 , 0.00231) 
-  -  1.29  0.2649  0.4382  < 0.0001  0.9827  -  -  - 
b2  1/C 
0.00219 
(0.00213, 0.00226)  -  -  1.76  0.0973  0.0078  < 0.0001  0.9879  -  -  - 
b3  1/C
2 
0.00211 
(0.00205, 0.00217) 
-  -  1.49  0.1751  0.0002  0.1825  0.9846  -  -  - 
b4  1/PAR 
0.00219 
(0.00213, 0.00226) 
-  -  1.76  0.0973  0.1659  < 0.0001  0.9879  -  -  - 
b5  1/PAR
2 
0.00211 
(0.00205, 0.00217)  -  -  1.49  0.1751  0.1101  0.1825  0.9846  -  -  - 
c1  1 
7.1×10
-8 
(1.8×10
-8, 1.2×10
-7) 
0.0019 
(0.0017, 0.0022) 
0.0453 
(-0.1224, 0.2130)  0.61  0.7655  0.4138  < 0.0001  0.9846  0.926  0.942  0.553 
c2  1/C 
4.6×10
-8 
(1.0×10
-8, 8.1×10
-8) 
0.0021 
(0.0019, 0.0022) 
0.0004 
(-0.0159, 0.0167)  1.27  0.2824  0.0074  0.0015  0.9890  0.755  0.767  0.119 
c3  1/C
2 
4.0×10
-8 
(-7.0×10
-9, 8.6×10
-8) 
0.0021 
(0.0020, 0.0022) 
-0.0003 
(-0.0026, 0.0020) 
1.34  0.2489  0.0002  0.1527  0.9852  0.455  0.592  0.372 
c4  1/PAR 
4.5×10
-8 
(9.5×10
-9, 8.0×10
-8) 
0.0021 
(0.0019, 0.0022) 
0.0003 
(-0.0156, 0.0162) 
1.31  0.2635  0.1584  0.0021  0.9890  0.746  0.759  0.120 
c5  1/PAR
2 
3.9×10
-8 
(-9.8×10
-9, 8.8×10
-8) 
0.0021 
(0.0020, 0.0022) 
-0.0003 
(-0.0025, 0.0019) 
1.34  0.2508  0.1083  0.1328  0.9849  0.445  0.591  0.382 
d1  1 
0.00128 
(0.00068, 0.00189) 
1.068 
(1.010, 1.125) 
-  0.81  0.6097  0.4199  < 0.0001  0.9842  0.996  0.996  - 
d2  1/C 
0.00168 
(0.00125, 0.00211) 
1.034 
(1.002, 1.067) 
-  1.41  0.2131  0.0075  0.0004  0.9887  0.988  0.988  - 
d3  1/C
2 
0.00196 
(0.00178, 0.00214) 
1.013 
(0.9976, 1.028) 
-  1.32  0.2539  0.0002  0.1038  0.9851  0.902  0.902  - 
d4  1/PAR 
0.00169 
(0.00127, 0.00211) 
1.033 
(1.002, 1.065) 
-  1.43  0.2066  0.1605  0.0005  0.9887  0.987  0.987  - 
d5  1/PAR
2 
0.00196 
(0.00178, 0.00214) 
1.013 
(0.9974, 1.028) 
-  1.30  0.2661  0.1085  0.0846  0.9848  0.897  0.897  - 
e1  1 
0.00108 
(0.00035, 0.00182) 
1.087 
(1.007, 1.167) 
0.0663 
(-0.1211, 0.2536)  0.85  0.5637  0.4219  < 0.0001  0.9840  0.998  0.998  0.628 
e2  1/C 
0.00161 
(0.00113, 0.00209) 
1.040 
(1.002, 1.078) 
0.0050 
(-0.0134, 0.0234)  1.55  0.1689  0.0076  0.0003  0.9885  0.991  0.991  0.279 
e3  1/C
2 
0.00187 
(0.00153, 0.00221) 
1.019 
(0.9929, 1.046) 
0.0011 
(-0.0024, 0.0046) 
1.44  0.2081  0.0002  0.1034  0.9850  0.973  0.967  0.731 
e4  1/PAR 
0.00162 
(0.00114, 0.00210) 
1.039 
(1.001, 1.076) 
0.0050 
(-0.0134, 0.0233)  1.56  0.1635  0.0004  0.0004  0.9885  0.991  0.990  0.290 
e5  1/PAR
2 
0.00188 
(0.00154, 0.00221) 
1.019 
(0.992, 1.046) 
0.0010 
(-0.0024, 0.0045) 
1.42  0.2173  0.1093  0.0844  0.9846  0.972  0.966  0.738 
f1  1 
1.0440 
(0.8158, 1.2710) 
0.00049 
(0.00044, 0.00053) 
-  25.35  < 0.0001  0.9672  0.0182  0.9159  0.907  0.907  - 
f2  1/C 
0.1584 
(0.0725, 0.2444) 
0.00087 
(0.00075, 0.00099) 
-  213.90  < 0.0001  0.0443  0.0003  0.6068  0.851  0.851  - 
f3  1/C
2  0.0312 
(0.0181, 0.0442) 
0.00112 
(0.00105, 0.00135) 
-  334.10  < 0.0001  0.0017  0.0015  0.1884  0.325  0.325  - 
f4  1/PAR  0.7612 
(0.5751, 0.9473) 
0.00057 
(0.00050, 0.00064) 
-  118.80  < 0.0001  0.7629  < 0.0001  0.7236  0.693  0.693  - 
f5  1/PAR
2  0.3889 
(0.2831, 0.4947) 
0.00098 
(0.00082, 0.00113) 
-  245.90  < 0.0001  0.8099  < 0.0001  0.4610  0.351  0.351  - 
§ Standard error of estimate 
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Although the  difference  of median  relative  prediction 
error  and  median  absolute  relative  prediction  error 
between  the  above  four  models  could  not  be 
considered  statistically  significant,  model  with  the 
lower  median  values  of  the  above  predictive 
performance  parameters  are  preferred.
31,35  However, 
the  95%  confidence  interval  for  the  parameter    of 
model  d3  includes  1  and  thus  the  model  could  be 
reduced to a more simplified form or b3. 
Application  of  the  weighted  least  squares  regression 
method with a proper weighting factor could result in 
better  estimation  of  the  unknown  concentration  near 
the lowest level of the analyte in the calibration curve 
(limit of quantitation).
22 Model b3 predicts the limit of 
quantitation  (10  ng/mL)  with  median  absolute 
prediction error of 7.7 % (Table 2). 
On the other hand with the above mentioned weighted 
regression  model,  it  is  possible  to  cover  the  entire 
range of calibration curve (up to 500 fold) using one 
simple  equation  with  good  accuracy  and  precision. 
Table  3  shows  the  accuracy  and  precision  of  the 
reported  high-performance  liquid  chromatography 
method for quantitation of propofol in human plasma. 
Since  selection  and  using  the  weighted  and/or  more 
complex  equation  for  the  calibration  curve  should  be 
justified,
24  the  presented  approach  of  choosing 
appropriate  weighted  model  for  determination  of 
propofol could address this issue. 
 
Table 2. Predictive performance parameters of the different propofol calibration models 
Model 
Relative prediction error (%)  Absolute relative prediction error (%)  Median  absolute 
relative prediction 
error(%) at 10 ng/mL  Median 
Lower 
confidence limit 
Upper 
confidence limit 
Median 
Lower 
confidence limit 
Upper 
confidence limit 
a1  -2.5  -11.9  9.8  11.9  9.5  15.0  348.0 
a2  -0.1  -10.2  12.7  12.3  10.2  15.4  21.8 
a3  3.1  -7.5  16.0  10.1  7.5  16.0  8.4 
a4  -0.1  -10.2  12.7  12.4  10.2  15.4  19.6 
a5  3.1  -7.5  16.0  10.1  7.5  16.0  8.4 
b1  -2.1  -12.2  10.1  11.6  10.1  14.7  13.1 
b2  0.1  -10.3  12.5  11.8  9.6  12.9  11.2 
b3  4.0  -6.8  17.0  9.4  6.0  17.0  7.7 
b4  0.1  -10.3  12.5  11.8  9.6  12.9  11.2 
b5  4.0  -6.8  17.0  9.4  6.0  17.0  8.4 
c1  6.5  4.1  12.2  6.5  4.1  12.2 
§not estimated 
c2  -3.5  -11.5  7.4  7.6  6.1  14.1  7.2 
c3  -3.1  -11.8  8.2  8.5  6.7  13.8  7.5 
c4  -3.4  -11.6  7.4  7.7  6.3  14.0  7.1 
c5  -3.0  -11.8  8.3  8.6  6.7  13.8  7.6 
d1  -2.5  -9.0  7.7  9.0  6.1  15.4  41.0 
d2  -2.5  -11.6  9.5  11.6  7.8  14.6  18.6 
d3  0.3  -9.3  12.6  11.5  9.3  12.9  8.9 
d4  -2.4  -11.5  9.6  11.5  7.9  14.6  18.0 
d5  0.4  -9.2  12.7  11.4  9.2  13.0  8.8 
e1  7.3  3.8  12.5  7.3  3.8  12.5  not estimated 
e2  -2.7  -11.7  9.0  9.2  7.0  13.8  17.1 
e3  -0.6  -10.0  11.5  11.5  8.0  13.2  7.4 
e4  -2.6  -11.7  9.0  9.3  7.1  13.8  17.1 
e5  -0.5  -10.0  11.6  11.6  7.9  13.1  7.4 
f1  7.8  1.8  19.6  7.8  1.8  18.3  not estimated 
f2  10.3  2.7  56.3  5.1  0.3  183.2  not estimated 
f3  33.9  29.4  60.1  4.0  0.3  241.2  not estimated 
f4  5.1  0.3  183.2  10.3  2.7  56.3  not estimated 
f5  4.0  0.3  241.2  33.9  29.4  60.1  not estimated 
§ Concentration could not predicted by the model 
 
 
Table 3. Results of accuracy and precision of the method 
Nominal 
concentration 
(ng/mL) 
Accuracy (%)  Precision (%) 
Intra-day  Inter-day  Intra-day  Inter-day 
10(
§LOQ)  94.8±4.5  109.6±10.4  8.7  12 
1000  102.3±3.6  93.3±10.1  3.5  11.8 
5000  109.4±5.8  114.5±9.0  5.4  11.2 
§ Limit of quantitation 
 
Conclusion 
In summary, with the presented approach of constructing 
calibration  equation,  it  is  possible  to  choose  the  best 
model  when  the  response  variable  is  heteroscedastic 
especially  over  a  broad  range  of  concentration  for 
propofol  and  any  other  analyte  with  such  a  wide 
expected range of concentrations in real samples.  
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